Welcome to our dedicated page for Quipt Home Medical news (Ticker: QIPT), a resource for investors and traders seeking the latest updates and insights on Quipt Home Medical stock.
Quipt Home Medical Corp. (QIPT) generates a steady flow of news as a U.S.-based home medical equipment provider focused on end-to-end respiratory care and in-home chronic disease management. Company press releases regularly discuss its role in providing in-home monitoring and disease management services for patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions in the United States healthcare market.
News coverage for QIPT commonly includes financial results and operational updates. For example, Quipt issues quarterly and annual earnings releases that highlight revenue trends, recurring revenue from equipment rentals and respiratory resupplies, Adjusted EBITDA, and operational metrics such as the number of unique patients served and set-ups or deliveries completed. These releases often include management commentary on business performance, revenue stabilization, and the contribution of acquisitions and partnerships.
Another major category of Quipt news involves strategic transactions. The company has announced acquisitions of durable medical equipment providers and a joint venture interest in Hart Medical Equipment, as well as a preferred provider agreement with Ballad Health. These items describe how Quipt works with health systems and hospitals to integrate home medical equipment and respiratory care into hospital discharge processes and post-acute care coordination.
More recently, Quipt’s news has featured corporate and M&A developments, including activist shareholder commentary and, most notably, the December 2025 announcement of a definitive Arrangement Agreement under which a special purpose acquisition vehicle funded by affiliates of Kingswood Capital Management and Forager Capital Management will acquire all outstanding Quipt shares for cash. This transaction, if completed, is expected to result in Quipt becoming a privately held company and its shares being delisted from The Nasdaq Capital Market and the Toronto Stock Exchange.
Investors and observers using this QIPT news page on Stock Titan can review these earnings announcements, acquisition and joint venture updates, health system partnership news, and transaction-related disclosures in one place, helping them understand how Quipt’s home medical equipment and respiratory care strategy is reflected in its public communications.
Quipt Home Medical Corp. (NASDAQ:QIPT) announced its Fiscal Q3 2022 earnings conference call scheduled for August 16, 2022, at 10:00 a.m. EDT. The call will be accessible via toll-free numbers and a live audio webcast on the company's investor website. Quipt focuses on respiratory care and aims to expand its services for chronic disease management. The company's strategy emphasizes increasing annual revenue per patient by consolidating service offerings and enhancing patient convenience.
Quipt Home Medical Corp. (NASDAQ:QIPT) has announced a contract with Cardinal Health for supplying disposable medical supplies nationwide. This partnership aims to enhance Quipt's distribution channels across its 94 locations, decrease costs, and facilitate the expansion of its healthcare services. The contract is expected to leverage existing national insurance agreements and provide synergies for future acquisitions, boosting Quipt's market presence. The CEO expressed optimism about the contract's potential to drive growth in 2022 and beyond.
Quipt Home Medical Corp. (NASDAQ: QIPT) has announced a webcasted presentation scheduled for August 11, 2022, as part of the 42nd Annual Canaccord Growth Conference. The conference will take place in-person at the InterContinental Boston from August 8th to 11th. During the presentation, management will discuss the company’s focus on end-to-end respiratory care and strategies for expanding its offerings in chronic disease management. The live webcast can be accessed through Quipt's investor website, with a replay available afterward.
Quipt Home Medical Corp. has acquired Hometown Medical, LLC in Mississippi, expanding its operations significantly. The acquisition, which adds two locations and over 11,000 active patients, is projected to boost annual revenues by approximately $7 million and increase Adjusted EBITDA by $1.4 million post-integration. Quipt now serves over 200,000 active patients and boasts a network of over 21,600 referring physicians. This strategic move targets patients suffering from Chronic Obstructive Pulmonary Disease (COPD), capitalizing on high demand in the region.
Quipt Home Medical Corp. has acquired Access Respiratory Homecare, enhancing its position in the home medical equipment industry. This strategic acquisition adds approximately $6.5 million in annual revenues and an estimated $1.3 million in Adjusted EBITDA post integration. With this acquisition, Quipt expands its referring physician network to over 20,600 and increases its active patient base to over 190,000. Quipt is also reiterating its annual run-rate revenue outlook for 2022 at $180-$190 million.
Quipt Home Medical Corp. (NASDAQ:QIPT) has acquired NorCal Respiratory, enhancing its presence in California with three new locations. This acquisition is expected to add approximately $3.2 million in annualized revenues and $650,000 to Adjusted EBITDA post-integration. Quipt's active patient count will increase to around 184,000, supported by a network of over 19,600 physicians. The deal, valued at approximately $3.1 million in cash, aligns with Quipt’s growth strategy focused on respiratory care, particularly in regions with a high prevalence of COPD.
Quipt Home Medical Corp. (NASDAQ:QIPT) announced its preliminary inclusion in the Russell Microcap Index, effective June 27, 2022. This milestone is expected to enhance the Company’s visibility within the investment community as it aims to grow in the home respiratory care market. CEO Greg Crawford highlighted that this membership reflects Quipt's substantial growth and strategic positioning. The Russell Microcap Index is recognized by investment managers, with $12 trillion in assets benchmarked against it, potentially driving investment towards Quipt.
Quipt Home Medical Corp. (NASDAQ:QIPT) reported a 38% revenue growth year-over-year, reaching $33.6 million for Q2 2022, and a 31% increase in adjusted EBITDA of $7.0 million. The company's net income turned positive at $5 million compared to a loss of $12.5 million a year earlier. With a 77% recurring revenue rate and a solid patient base growth of 37%, management projects an annual run-rate revenue of $180-$190 million by the end of 2022.
Additionally, several acquisitions have bolstered its market presence.
Quipt Home Medical Corp. (NASDAQ: QIPT) will host its Fiscal Q2 2022 earnings conference call on May 17, 2022, at 10:00 a.m. (EST). This event highlights the company's commitment to transparency and investor engagement. The call will be accessible via audio webcast on their investor website. Quipt focuses on providing in-home monitoring and disease management services for chronic conditions, aiming to expand their service offerings while increasing annual revenue per patient. For more details, visit their website.
Quipt Home Medical Corp. has announced a significant national insurance contract with one of the top five health insurers in the U.S., marking a pivotal moment in its growth strategy. This contract facilitates entry into new states, enhancing their operational reach and patient access. CEO Greg Crawford emphasized the contract's potential for accelerating their expansion and capturing patient volume, while also indicating plans to pursue additional national contracts to further strengthen their business model and service offerings.